Aptevo Therapeutics Inc (NASDAQ:APVO)’s traded shares stood at 0.13 million during the last session, with the company’s beta value hitting 5.63.The APVO share’s 52-week high remains $485.37, putting it -15866.12% down since that peak but still an impressive 7.57% since price per share fell to its 52-week low of $2.81. The company has a valuation of $9.80M, with an average of 0.78 million shares in intraday trading volume over the past 10 days and average of 2.40 million shares over the past 3 months.

Aptevo Therapeutics Inc (NASDAQ:APVO) trade information

The 5-day price performance for the stock is -5.88%, and -38.89% over 30 days. With these gigs, the year-to-date price performance is -98.77%. Short interest in Aptevo Therapeutics Inc (NASDAQ:APVO) saw shorts transact 11418.0 shares and set a 0.03 days time to cover.

APVO Dividends

Aptevo Therapeutics Inc has its next earnings report out on 2025-May-15. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Aptevo Therapeutics Inc (NASDAQ:APVO)’s Major holders

Aptevo Therapeutics Inc insiders hold 9.95% of total outstanding shares, with institutional holders owning 0.43% of the shares at 0.48% float percentage. In total, 0.43% institutions holds shares in the company.

We also have Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Aptevo Therapeutics Inc (APVO) shares. Going by data provided on Apr 30, 2025, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund holds roughly 420.0 shares. This is just over 0.01% of the total shares, with a market valuation of $1276.0. Data from the same date shows that the other fund manager holds a little less at 3.0, or 0.00% of the shares, all valued at about 9.0.